Oncoxin in combination with Surafenib is safe and results in improved survival in patients with hepatocellular carcinoma (HCC)

To assess therapeutic efficacy and safety of Oncoxin plus Surafenib in hepatocellular carcinoma

To see if there is reduction in serum alpha fetoprotein level in hepatocellular carcinoma patients after administration of Oncoxin plus Surafenib

To see if there is reduction tumor size and or number in hepatocellular carcinoma patients after administration of Oncoxin plus Surafenib

To see if there is improvement of quality of life in hepatocellular carcinoma patients after administration of Oncoxin plus Surafenib

To see if there is improved survival in hepatocellular carcinoma patients after administration of Oncoxin plus Surafenib

Inclusion Criteria:

• Patients with HCC irrespective of etiology, age, gender and status of underlying liver disease.
• Patients with HCC who are not suitable candidates for established modalities of treatment i.e. surgery and/or chemotherapy.
• Patients with HCC who have evidence of tumor metastasis
• Patients with HCC who are voluntarily unwilling to take established modalities of treatment i.e. surgery and/or chemotherapy.
• Patients with HCC in whom all possible treatment options have been exhausted.

Exclusion Criteria:

• Patients with HCC who are suitable candidates for established modalities of treatment i.e. surgery and/or chemotherapy.
• Patients with HCC who have no evidence of tumor metastasis
• Patients with HCC who are willing to take established modalities of treatment i.e. surgery and/or chemotherapy.
• Patients with HCC who are voluntarily unwilling to be included in the trial